CTC NOTICE OF MODIFICATIONS
Version 2.0 Publish Date: April 30, 1999
Fever (in the absence of neutropenia, where neutropenia is defined as AGC < 1.0 x 109/L)
Also consider Allergic... Note: The temperature... Hot flashes/flushes... Rigors, chills
The Also consider for Weight gain was changed to include the term Pleural effusion (non-malignant).
Weight gain Also consider Ascites…
Weight gain associated with Veno-Occlusive Disease (VOD) for BMT studies, if specified in the protocol.
Also consider Ascites… Weight loss Also consider Vomiting...
The Also consider Ascites, Edema, Pleural effusion (non-malignant) was added to Weight gain associated with Veno-Occlusive Disease for BMT studies.
The spelling for the word ascites was corrected.
Constitutional Symptoms - Other (Specify, __________)
Bruising (in absence of grade 3 or 4 thrombocytopenia)
Note: Bruising resulting...
The adverse event Dermatitis, focal (associated with high-dose chemotherapy and bone marrow transplant) originally listed between Bruising and Dry skin was renamed Rash/dermatitis and moved to page 9.
Erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)
Flushing Hand-foot skin reaction
Injection site reaction
Cancer Therapy Evaluation Program Common Toxicity Criteria, Version 2.0 DCTD, NCI, NIH, DHHS March 1998
Revised March 23, 1998